The UK and US have announced a important trade agreement that will guarantee no import taxes on UK medicine exports going into the American market.
The Terms of the Accord
As part of the deal, the UK has committed to raise spending on pharmaceuticals through the National Health Service (NHS). This commitment guarantees that tariffs on these key goods will remain at zero for a period of the next three years.
This deal follows previous statements to hike import taxes on branded drug imports, with increases mentioned as high as one hundred percent.
"This agreement between the United Kingdom strengthens the global environment for new treatments and brings much-needed balance to U.S.–U.K. drug exports," a statement declared.
Commercial Importance
Medicines represent one of the Britain's largest goods shipped to the United States, which is by far the biggest market for leading UK drugmakers.
Statistics reveal that in the 12 months to the end of September, the UK shipped medicines totaling billions to the US. This amount represented a significant portion of total UK exports in that timeframe.
"This agreement protects jobs, stimulates funding and sets the stage for the UK to become a global hub for medical research," the Business and Trade Secretary commented.
Key UK Commitments
The pact includes several notable pledges from the United Kingdom:
- Revised Affordability Limit: The UK will lift the cost ceiling at which it considers new therapies to be unaffordable by twenty-five percent.
- Increased NHS Spending: There is a target to increase total NHS spending on medicines from 0.3 percent of GDP to 0.6 percent over the coming ten years.
- Payback Limit: The amount pharmaceutical firms must pay back to the NHS to prevent overspending will be capped at fifteen percent. Previously, rebates were more than twenty percent.
Recent Tensions
The pact comes amid a protracted dispute between the drug companies and the UK government over medicine costs and NHS adoption.
These tensions were intensified by claims that American customers were paying several times more for the identical medicines than patients in the UK and Europe.
Recently, several large pharmaceutical investments in the UK have been halted or abandoned, while multi-billion-dollar funding commitments have been directed toward projects in the United States.
A senior figure stated that the NHS needed to spend more on medicines, noting that its spending on drugs had declined as a proportion of its total funding over the past decade.
